Bli medlem
Bli medlem

Du är här


ExpreS2ion Biotechnologies: Strong Proof-of-Concept for cross-strain protective flu cVLP vaccine further strengthens confidence in Coronavirus vaccine

Dr. Wian de Jongh, CSO in ExpreS[2]ion and CEO of AdaptVac comments:

"These very promising results demonstrate the potential of the cVLP platform to be protective even after a single vaccine dose. In light of AdaptVac's focus on COVID-19, this is an extremely encouraging verification of the efficacy of the platform for respiratory viruses."

Paper reference: Vaccines 2020, 8, 389; doi:10.3390/vaccines8030389

About AdaptVac

AdaptVac ApS ( s a joint venture between ExpreS[2]ion Biotechnologies ApS and NextGen Vaccines ApS, owned by the inventors of the novel proprietary and ground-breaking capsid virus-like particle (cVLP) platform technology spun out from the University of Copenhagen. The Company aims to accelerate the development of highly efficient therapeutic and prophylactic vaccines within high value segments of oncology, infectious diseases and immunological disorders. Granting of the core patent in the U.S. has expanded AdaptVac's patent protection to include the full pipeline of vaccines and immunotherapies in development.

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telephone: +46 11 32 30 732


Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.